October 2000
Worldwide Biotech;Oct2000, Vol. 12 Issue 10, p5
Trade Publication
Introduces Actonel, a treatment and prevention drug for postmenopausal osteoporosis from Procter & Gamble Pharmaceuticals Canada Inc. and Aventis Pharma Incorporated.


Related Articles

  • Antiestrogenic action of raloxifene and tamoxifen: Today and tomorrow.  // JNCI: Journal of the National Cancer Institute;07/01/98, Vol. 90 Issue 13, p967 

    Discusses the availability of raloxifene to physicians as a bone maintenance therapy to prevent osteoporosis in postmenopausal women. Original name given to raloxifene; In-depth look at raloxifene; Antiestrogenic action of raloxifene; Reference to the estrogen drug tamoxifen; Difference between...

  • Efficacy and safety of a bisphosphonate dosed once weekly . Baran, Daniel // Geriatrics;Mar2001, Vol. 56 Issue 3, p28 

    Evaluates the efficacy and safety of biphosphonate alendronate in treating and preventing postmenopausal osteoporosis. Clinical impact of osteoporosis; Steps in a bone remodeling cycle; Evaluation of other antiresorptive agents.

  • FDA approves Duavee for menopausal symptoms, osteoporosis.  // Endocrine Today;Nov2013, Vol. 11 Issue 11, p9 

    The article reports on the novel therapy called Duavee that has been approved by the U.S. Food and Drug Administration (FDA) for treatment of moderate-to-severe vasomotor symptoms associated with menopause and prevention of postmenopausal osteoporosis in women with a uterus.

  • Skeletal effects of oral oestrogen compared with subcutaneous oestrogen and testosterone in postmenopausal women. Savvas, M.; Studd, J.W.W.; Fogelman, I.; Dooley, M.; Montgomery, J.; Murby, B. // BMJ: British Medical Journal (International Edition);7/30/88, Vol. 297 Issue 6644, p331 

    Compares oral and implanted estrogens for the prevention of postmenopausal osteoporosis in Great Britain. Administration of oral treatment; Increase in bone density; Effectivity of subcutaneous estrogen than oral estrogen.

  • Long-term effect of oestrogen replacement therapy on bone mass as measured by dual photon absorptiometry. Al-Azzawi, F.; Hart, D.M.; Lindsay, R. // British Medical Journal (Clinical Research Edition);5/16/1987, Vol. 294 Issue 6582, p1261 

    Investigates on the long term effect of oestrogen replacement therapy on bone mass. Measurement of bone mass in the lumbar spines and femoral neck of patients; Importance of preservation of bone mass in reduction the incidence of fractures; Effect of oestrogen on bone mass at the major fracture...

  • Growth hormone beneficial in osteoporosis, no effects on QOL.  // PharmacoEconomics & Outcomes News;Sep2015, Vol. 737 Issue 1, p29 

    The article reports on the findings of a study conducted in Sweden, that growth hormone (GH) treatment has beneficial effects on bone measurements and fracture incidence after 10 years in women with postmenopausal osteoporosis and does not affect the quality of life of the patients.

  • Emerging and future therapies for the treatment of bone loss associated with chronic inflammation. Haynes, D. R. // Inflammopharmacology;Dec2006, Vol. 14 Issue 5/6, p193 

    Currently there are many emerging therapies for the treatment of chronic osteoporosis. This is a major problem world wide and particularly of concern in post-menopausal women. This has offered a large expanding market for the pharmaceutical industry and consequently large amounts of money and...

  • Comparison of the Effects of Alendronate and Alfacalcidol on Hip Bone Mineral Density and Bone Turnover in Japanese Men Having Osteoporosis or Osteopenia with Clinical Risk Factors for Fractures. Iwamoto, Jun; Sato, Yoshihiro; Uzawa, Mitsuyoshi; Takeda, Tsuyoshi; Matsumoto, Hideo // Yonsei Medical Journal;8/31/2009, Vol. 50 Issue 4, p474 

    Purpose: The comparative effects of alendronate and alfacalcidol on bone mineral density (BMD) and bone turnover have already been established in postmenopausal women with osteoporosis. An open-labeled prospective study was conducted to compare the treatment effects of alendronate and...

  • Alendronic acid.  // Reactions Weekly;6/16/2007, Issue 1156, p7 

    The article presents the medical case of a 62-year-old women with postmenopausal osteoporosis who developed persistent polyarticular synovitis shortly after starting therapy with alendronic acid. Alendronic acid was stopped and prednisolone was started for persistent synovitis, resulting in a...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics